Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 297-302

  Hui, Christy L M ^a   Wong, Gloria H Y ^a   Tang, Jennifer Y M ^a   Chang, W C ^a   Chan, Sherry K W ^a   Lee, Edwin H M ^a   Lam, May M L ^a   Chiu, Cindy P Y ^a   Law, C W ^b   Chung, Dicky W S ^c   Tso, Steve ^d   Pang, Edwin P F ^c   Chan, K T ^d   Wong, Y C ^c   Mo, Flora Y M ^c   Chan, Kathy P M ^e   Hung, S F ^e   Honer, William G ^f   Chen, Eric Y H ^a,g  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c TAI PO HOSPITAL   (Hong Kong)

^d CASTLE PEAK HOSPITAL   (Hong Kong)

^e KWAI CHUNG HOSPITAL   (Hong Kong)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Double blind; First episode schizophrenia; Maintenance; Randomized controlled trial; Relapse prevention

Indexed keywords

DOPAMINE; PLACEBO; QUETIAPINE;

ADULT; ARTICLE; BRIEF PSYCHOTIC DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EMPLOYMENT STATUS; EYELID REFLEX; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; ONSET AGE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOIDISM; SCHIZOPHRENIFORM DISORDER; SCHIZOTYPAL PERSONALITY DISORDER; SEMANTICS; SENSORY DYSFUNCTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERBAL MEMORY;

DOUBLE BLIND; FIRST-EPISODE SCHIZOPHRENIA; MAINTENANCE; RANDOMIZED CONTROLLED TRIAL; RELAPSE PREVENTION;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884142945     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.08.010     Document Type: Article

References (38)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. IJNP 2004, 7(Suppl. 1):1-5.
2. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 1992, 6(3):201-208.
3. Alvarez-Jimenez M., Priede A., Hetrick S.E., Bendall S., Killackey E., Parker A.G., McGorry P.D., Gleeson J.F. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr. Res. 2012, 139(1-3):116-128.
4. Amador X.F., Flaum M., Andreasen N.C., Strauss D.H., Yale S.A., Clark S.C., Gorman J.M. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch. Gen. Psychiatry 1994, 51(10):826-836.
5. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa.
6. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa.
7. Angermeyer M.C., Goldstein J.M., Kuehn L. Gender differences in schizophrenia: rehospitalization and community survival. Psychol. Med. 1989, 19(2):365-382.
8. APA Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC, (revised). 4th edn.
9. Bradford D.W., Perkins D.O., Lieberman J.A. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003, 63(21):2265-2283.
10. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8(3):470-484.
11. Chen E.Y., Hui C.L., Dunn E.L., Miao M.Y., Yeung W.S., Wong C.K., Chan W.F., Tang W.N. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr. Res. 2005, 77(1):99-104.
12. Chen E.Y., Hui C.L., Chan R.C., Dunn E.L., Miao M.Y., Yeung W.S., Wong C.K., Chan W.F., Tang W.N. A 3-year prospective study of neurological soft signs in first-episode schizophrenia. Schizophr. Res. 2005, 75(1):45-54.
13. Chen E.Y., Hui C.L., Lam M.M., Chiu C.P., Law C.W., Chung D.W., Tso S., Pang E.P., Chan K.T., Wong Y.C., Mo F.Y., Chan K.P., Yao T.J., Hung S.F., Honer W.G. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010, 341:c4024.
14. Crow T.J., MacMillan J.F., Johnson A.L., Johnstone E.C. The Northwick Park study of first episodes of schizophrenia II: a randomized controlled trial of prophylactic neuroleptic treatment. Br. J. Psychiatry 1986, 148:120-127.
15. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148(11):1474-1486.
16. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 1990, 521(1-2):311-315.
17. Foerster A., Lewis S., Owen M., Murray R. Pre-morbid adjustment and personality in psychosis: effects of sex and diagnosis. Br. J. Psychiatry 1991, 158:171-176.
18. Geijo-Barrientos E., Pastore C. The effects of dopamine on the subthreshold electrophysiological responses of rat prefrontal cortex neurons in vitro. Eur. J. Neurosci. 1995, 7(3):358-366.
19. Guy W. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ. No. ADM 76-338) 1976, 218-222. National Institute of Mental Health, Rockville, MD.
20. Häfner H., Riecher-Rössler A., Hambrecht M., Maurer K., Meissner S., Schmidtke A., Fatkenheuer B., Loffler W., van der Heiden W. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr. Res. 1992, 6(3):209-223.
21. Haro J.M., Eaton W.W., Bilker W.B., Mortensen P.B. Predictability of rehospitalization for schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1994, 244(5):241-246.
22. Heinrichs D.W., Buchanan R.W. Significance and meaning of neurological signs in schizophrenia. Am. J. Psychiatry 1988, 145(1):11-18.
23. Hides L., Dawe S., Kavanagh D.J., Young R.M. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br. J. Psychiatry 2006, 189:137-143.
24. Hogarty G.E., Ulrich R.F. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J. Psychiatr. Res. 1998, 32(3-4):243-250.
25. Johnstone E.C., MacMillan J.F., Frith C.D., Benn D.K., Crow T.J. Further investigation of the predictors of outcome following first schizophrenic episodes. Br. J. Psychiatry 1990, 157:182-189.
26. Kane J.M., Rifkin A., Quitkin F., Nayak D., Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch. Gen. Psychiatry 1982, 39(1):70-73.
27. Karson C.N. Spontaneous eye-blink rates and dopaminergic systems. Brain 1983, 106:643-653.
28. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
29. Larsen T.K., Moe L.C., Vibe-Hansen L., Johannessen J.O. Premorbid functioning versus duration of untreated psychosis in 1year outcome in first-episode psychosis. Schizophr. Res. 2000, 45(1-2):1-9.
30. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res. Brain Res. Rev. 2000, 31(2-3):371-384.
31. Lenior M.E., Dingemans P.M.A., Schene A.H., Linszen D.H. Predictors of the early 5-year course of schizophrenia: a path analysis. Schizophr. Bull. 2005, 31(3):781-791.
32. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002, 5(3):267-271.
33. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56(3):241-247.
34. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002, 57(2-3):209-219.
35. Rund B.R., Melle I., Friis S., Johannessen J.O., Larsen T.K., Midbøe L.J., Opjordsmoen S., Simonsen E., Vaglum P., McGlashan T. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr. Res. 2007, 91(1-3):132-140.
36. So E., Kam I., Leung C.M., Chung D., Liu Z., Fong S. The Chinese-bilingual SCID-I/P project: stage 1-reliability for mood disorders and schizophrenia. Hong Kong J. Psychiatry 2003, 13(1):7-18.
37. Tohen M., Stoll A.L., Strakowski S.M., Faedda G.L., Mayer P.V., Goodwin D.C., Kolbrener M.L., Madigan A.M. The McLean first-episode psychosis project: six-month recovery and recurrence outcome. Schizophr. Bull. 1992, 18(2):273-282.
38. Vaughn C.E., Snyder K.S., Jones S., Freeman W.B., Falloon I.R. Family factors in schizophrenic relapse: replication in California of British research on expressed emotion. Arch. Gen. Psychiatry 1984, 41(12):1169-1177.